Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor α, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor

Arthritis and Rheumatism

Volumn 58, Issue 8, 2008, Pages 2257-2267

  Rioja, Inmaculada ^a   Hughes, Fiona J ^a   Sharp, Catriona H ^a   Warnock, Linda C ^a   Montgomery, Doug S ^a   Akil, Mohammed ^b   Wilson, Anthony G ^b   Binks, Michael H ^a   Dickson, Marion C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMYLOID A PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CCL23 CHEMOKINE; CHEMOKINE; CILIARY NEUROTROPHIC FACTOR RECEPTOR ALPHA; COLONY STIMULATING FACTOR 1; CXCL11 CHEMOKINE; CXCL13 CHEMOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; FIBROBLAST GROWTH FACTOR 4; FOLLISTATIN; INFLIXIMAB; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 9; LYMPHOTACTIN; LYMPHOTOXIN BETA RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 2; NEUTROPHIL COLLAGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOSTATIN M; RHEUMATOID FACTOR; STEROID; STROMELYSIN 2; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DISCRIMINANT ANALYSIS; DISEASE ACTIVITY; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LOW DRUG DOSE; MALE; MEDICAL SCHOOL; PARTIAL LEAST SQUARES REGRESSION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYNOVITIS; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD137; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHEMOKINE CXCL13; CHEMOKINES, CC; FEMALE; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TRANSFORMING GROWTH FACTOR ALPHA; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 49449100341     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23667     Document Type: Article

References (36)

1. Wolfe F. The prognosis of rheumatoid arthritis: assessment of disease activity and disease severity in the clinic. Am J Med 1997;103:12-18S.
2. Mewar D, Coote A, Moore DJ, Marinou I, Keyworth J, Dickson MC, et al. Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis. Arthritis Res Ther 2006;8:R128.
3. Gardiner PV, Bell AL, Taggart AJ, Wright G, Kee F, Smyth A, et al. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis. Ann Rheum Dis 2005;64: 506-7.
4. Matsui T, Kuga Y, Kaneko A, Nishino J, Eto Y, Chiba N, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. Ann Rheum Dis 2007;66:1221-6.
5. Klimiuk PA, Sierakowski S, Chwiecko J. Serum interleukin 6 (IL-6A) concentration correlates with matrix metalloproteinases and their tissue inhibitors in rheumatoid arthritis. Pol Arch Med Wewn 2003;109:119-23. In Polish.
6. Houssiau FA, Devogelaer JP, Van Damme J, Nagant de Deuxchaisnes C, Van Snick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988;31:784-8.
7. Arvidson NG, Gudbjornsson B, Elfman L, Ryden AC, Totterman TH, Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann Rheum Dis 1994;53:521-4.
8. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998;9:145-54.
9. Drynda S, Ringel B, Kekow M, Kuhne C, Drynda A, Glocker MO, et al. Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFα therapy. Pathol Res Pract 2004;200:165-71.
10. Dessein PH, Joffe BI, Singh S. Biomarkers of endothelial dysfunction, cardiovascular risk factors and atherosclerosis in rheumatoid arthritis. Arthritis Res Ther 2005;7:R634-43.
11. Tchetverikov I, Ronday HK, Van El B, Kiers GH, Verzijl N, TeKoppele JM, et al. MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis. Ann Rheum Dis 2004;63:881-3.
12. Charles P, Elliott MJ, Davis D, Potter A, Kalden JR, Antoni C, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-α therapy in rheumatoid arthritis. J Immunol 1999;163:1521-8.
13. Arvidson NG, Larsson A, Larsen A. Disease activity in rheumatoid arthritis: fibrinogen is superior to the erythrocyte sedimentation rate. Scand J Clin Lab Invest 2002;62:315-9.
14. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
15. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
16. Schweitzer B, Roberts S, Grimwade B, Shao W, Wang M, Fu Q, et al. Multiplexed protein profiling on microarrays by rolling-circle amplification. Nat Biotechnol 2002;20:359-65.
17. Moody MD, Van Arsdell SW, Murphy KP, Orencole SF, Burns C. Array-based ELISAs for high-throughput analysis of human cytokines. Biotechniques 2001;31:186-90, 192-4.
18. Barker M, Rayens W. Partial least squares for discrimination. J Chemometrics 2003;17:166-73.
19. Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, Lindgren F, et al. Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 2004;380:419-29.
20. Shao Y, Tseng CH. Sample size calculation with dependence adjustment for FDR-control in microarray studies. Stat Med 2007;26:4219-37.
21. Kevin Chu. An introduction to sensitivity, specificity, predictive values and likelihood ratios. Emerg Med Australas 1999;11: 175-81.
22. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care 2004;8:508-12.
23. Uson J, Balsa A, Pascual-Salcedo D, Cabezas JA, Gonzalez-Tarrio JM, Martin-Mola E, et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997;24:2069-75.
24. Manicourt DH, Poilvache P, Van Egeren A, Devogelaer JP, Lenz ME, Thonar EJ. Synovial fluid levels of tumor necrosis factor α and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis. Arthritis Rheum 2000;43:281-8.
25. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. Arthritis Res Ther 2005;7:R784-95.
26. Michel J, Langstein J, Hofstadter F, Schwarz H. A soluble form of CD137 (ILA/4-1BB), a member of the TNF receptor family, is released by activated lymphocytes and is detectable in sera of patients with rheumatoid arthritis. Eur J Immunol 1998;28:290-5.
27. Jung HW, Choi SW, Choi JI, Kwon BS. Serum concentrations of soluble 4-1BB and 4-1BB ligand correlated with the disease severity in rheumatoid arthritis. Exp Mol Med 2004;36:13-22.
28. Wolfe F, Michaud K, Pincus T, Furst D, Keystone E. The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: discordance between assessment measures and limitations in questionnaire use for regulatory purposes. Arthritis Rheum 2005;52: 3873-9.
29. Tak PP, Hintzen RQ, Teunissen JJ, Smeets TJ, Daha MR, van Lier RA, et al. Expression of the activation antigen CD27 in rheumatoid arthritis. Clin Immunol Immunopathol 1996;80: 129-38.
30. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000;406:309-14.
31. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80.
32. Gudewill S, Pollmacher T, Vedder H, Schreiber W, Fassbender K, Holsboer F. Nocturnal plasma levels of cytokines in healthy men. Eur Arch Psychiatry Clin Neurosci 1992;242:53-6.
33. Ueno A, Yamamura M, Iwahashi M, Okamoto A, Aita T, Ogawa N, et al. The production of CXCR3-agonistic chemokines by synovial fibroblasts from patients with rheumatoid arthritis. Rheumatol Int 2005;25:361-7.
34. Kawaji H, Yokomura K, Kikuchi K, Somoto Y, Shirai Y. Macrophage colony-stimulating factor in patients with rheumatoid arthritis. Nippon Ika Daigaku Zasshi 1995;62:260-70. In Japanese.
35. Danks L, Sabokbar A, Gundle R, Athanasou NA. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 2002;61:916-21.
36. Maruotti N, Cantatore FP, Crivellato E, Vacca A, Ribatti D. Angiogenesis in rheumatoid arthritis. Histol Histopathol 2006;21: 557-66.